Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialJAMA Oncol 2022 Sep 01;[EPub Ahead of Print], NM Tannir, N Agarwal, C Porta, NJ Lawrence, R Motzer, B McGregor, RJ Lee, RK Jain, N Davis, LJ Appleman, O Goodman, WM Stadler, S Gandhi, DM Geynisman, R Iacovelli, B Mellado, JM Sepúlveda Sánchez, R Figlin, T Powles, L Akella, K Orford, B Escudier
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.